Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Equity Average (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Equity Average for 15 consecutive years, with $642.9 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 5.66% year-over-year to $642.9 million; the TTM value through Mar 2026 reached $642.9 million, down 5.66%, while the annual FY2025 figure was $663.7 million, 11.89% up from the prior year.
  • Equity Average hit $642.9 million in Q1 2026 for Corcept Therapeutics, roughly flat from $639.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $681.4 million in Q1 2025 and bottomed at $391.8 million in Q1 2022.
  • Average Equity Average over 5 years is $547.8 million, with a median of $527.3 million recorded in 2024.
  • Year-over-year, Equity Average fell 24.23% in 2022 and then surged 39.83% in 2024.
  • Corcept Therapeutics' Equity Average stood at $487.6 million in 2022, then fell by 0.7% to $484.2 million in 2023, then skyrocketed by 36.15% to $659.2 million in 2024, then dropped by 2.94% to $639.9 million in 2025, then increased by 0.48% to $642.9 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $642.9 million, $639.9 million, and $633.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.